Effect of Intravenous Albumin Administration on HEMATOM Volume after Hemorrhagic Stroke


1 Department of Neurology, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran.

2 General Practitioner


Background and Objective: The aim of this study was to evaluate the effect of albumin in hematom volume after hemorrhagic stroke.
Subjects and Methods: The study was conducted in a randomized clinical trial; patients with hemorrhagic stroke in 24 hours of onset were included. Patients were divided into two groups, the first group was treated with intravenous albumin (1 g/Kg) and second group treated similarly with normal saline as placebo. Hematom volume was calculated before and at the end of treatment. Analyzes of data was made using Chi square and T-Test. Level of disability at baseline and end of treatment were compared with the NIHSS.
Results: From 61 patients were studied; 31 patients treated with albumin and 30 patients received placebo. Patients were matched for age, sex and risk factors. Mean changes in hematoma volume in the control group was 2.88(SD=1.42)ml and in the placebo group was 1.75(SD=1.27) ml. The differences observed between the two groups was statistically significant (P= 0.002). In the control group the mean change in NIHSS was 2.83(SD=1.26) and the median change was 3 and in the case group the mean change in NIHSS was 1.59(SD=1.21) and the median changes was 1. The difference between the two groups was statistically significant (P <0.001).
Conclusion: The results of this study showed that the use of intravenous albumin in patients with hemorrhagic stroke can further reducing the size of the hematoma and the patient's neurological deficits with possible better outcomes.


1-Ginsberg MD, Palesch YY, Hill MD. The ALIAS (ALbumin In Acute Stroke) phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans 2006;34(Pt 6):1323-6.
2-Kurth TKase CSBerger KSchaeffner ESBuring JEGaziano JM. Smoking and the risk of hemorrhagic stroke in men. Stroke 2003;34(5):1151-5.  
3-Thom TJ. Stroke mortality trends. An international perspective. Ann Epidemiol 1993;3(5):509–18.
4-Fogelholm R, Nuutila M, Vuorela AL. Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985–89: incidence, case fatality rate, and functional outcome. J Neurol Neurosurg Psychiatry 1992;55(7):546–52.
5-Belayev L, Saul I, Busto R, Danielyan K, Vigdorchik A, Khoutorova L, et al. Albumin treatment reduces neurological deficit and protects blood-brain barrier integrity after acute intracortical hematoma in the rat. Stroke 2005;36(2):326-31.
6-Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 1992;326(11):733-6.
7-Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke 2002;33(4):1077–84.
8-Dziedzic T, Pera J, Slowik A, Gryz-Kurek EA, Szczudlik A. Hypoalbuminemia in acute ischemic stroke patients: frequency and correlates. Eur J Clin Nutr 2007;61(11):1318-22.
9-Famakin B, Weiss P, Hertzberg V, McClellan W, Presley R, Krompf K.  Hypoalbuminemia predicts acute stroke mortality: Paul Coverdell Georgia Stroke Registry. J Stroke Cerebrovasc Dis 2010;19(1):17-22.
10-Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32(2):553- 60
11-Suarez J, Shannon L, Zaidat OOSuri MFSingh GLynch Get al. Effect of human albumin administration on clinical outcome and hospital cost in paitents with subarachnoid hemorrhage. J Neurosurg 2004;100(4):585-90.
12-Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect ofdelayed albumin hemodilution on infarction volume and brain edemaafter transient middle cerebral artery occlusion in rats. J Neurosurg 1997;87:595–601.
13-Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke 1998;29(12):2587–99.
14-Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol 2001;428(2):193–201.
15-Belayev L, Saul I, Huh PW, Finotti N, Zhao W, Busto R, et al. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res 1999;845(1):107–11.
16-Belayev L, Alonso OF, Huh PW, Zhao W, Busto R, Ginsberg MD. Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injuryin rats. J Neurotrauma 1999;16(6):445–53.
17-Giroud M, Gras P, Chadan N, Beuriat P, Milan C, Arveux P, et al. Cerebral haemorrhage in a French prospective population study. J Neurol Neurosurg Psychiatry1991;54(7):595-8.
18-Thrift AG, Mc Neil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998;31(6):1223-9.
19-Wagner KR, Xi G, Hua Y, Kleinholz M, de Courten-Myers GM, Myers RE. Early metabolic alterations in edematous perihematomal brain regions following experimental intracerebral hemorrhage. J Neurosurg 1998;88(6):1058-65.
20-Hickenbottom SL, Grotta JC, Strong R, Denner LA, Aronowski J. Nuclear factor-kappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke 1999;30(11):2472-7.